C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA

C4 Therapeutics (CCCC) announced that its partner Biogen (BIIB) has had its investigational new drug, IND, application for BIIB142 accepted by the U.S. Food and Drug Administration, FDA. “We are thrilled to see Biogen quickly advance the IRAK4 degrader that resulted from our collaboration toward the clinic in the hopes this molecule may bring a new treatment option to patients with autoimmune disease,” said Paige Mahaney, Ph.D., chief scientific officer of C4 Therapeutics. “Our long-standing collaboration with Biogen helped C4T build and deepen capabilities across our platform as we worked together to develop degraders for a broad range of target classes and therapeutic areas to reach a sizeable number of patients with unmet needs. We look forward to Biogen’s continued progress with BIIB142, as well as the second development candidate delivered under our collaboration.”